KIOXIA-HOLDINGS
Kioxia Holdings Corporation , the world leader in memory solutions, today announced the appointment of Michael R. Splinter as an independent director, effective immediately. Mr. Splinter is a 40-year veteran of the semiconductor industry and brings various business and technology experience that will help drive sustainable growth at Kioxia.
“We are excited to welcome Michael to our board during an important time as Kioxia continues to evolve as an independent company,” said Nobuo Hayasaka, representative director, president and CEO of Kioxia Holdings Corporation. “Michael’s unique combination of extensive knowledge of the semiconductor industry and leadership of large, complex organizations make him a great addition to an already deep and experienced board of directors. We look forward to his valuable perspectives as Kioxia enters its next phase of growth.”
Mr. Splinter served as President and CEO of Applied Materials from 2003 to 2012 and as chairman of the board of directors since 2009 until he retired in June 2015, leading the company to record revenue and profits during his tenure. Prior to joining Applied Materials, he served at Intel Corporation as an executive. Mr. Splinter currently serves as an external director of Taiwan Semiconductor Manufacturing Company (TSMC) and as chairman of NASDAQ, Inc. in the United States. Mr. Splinter holds a Master’s degree in electrical and computer engineering, and an honorary Ph.D. in electrical and computer engineering from the University of Wisconsin Madison.
“I am thrilled that Mike is joining the Kioxia board” said Stacy J. Smith, Executive Chairman of Kioxia. “Mike will be a pivotal addition to our board and will add greatly to our quest to build a world class governance structure to couple with our leading technology and position in the industry, and I look forward to working with him as we execute on our ambitious business strategy”.
“I'm excited and honored to join Kioxia's Board and collaborate with my fellow directors and the leadership team to contribute to the company’s mission of uplifting the world with memory,” said Mr. Splinter. “Throughout my career, I’ve had multiple opportunities to help companies grow strategically. I look forward to bringing my expertise and experience to Kioxia as a new board member. ”
About Kioxia Holdings Corporation
Kioxia is a world leader in memory solutions, dedicated to the development, production and sale of flash memory and solid state drives (SSDs). In April 2017, its predecessor Toshiba Memory was spun off from Toshiba Corporation, the company that invented NAND flash memory in 1987. The company pioneers cutting-edge memory solutions and services that enrich people's lives and expand society's horizons. Kioxia's innovative 3D flash memory technology, BiCS FLASH™, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, SSDs, automotive and data centers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200630005404/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Registrar Corp Acquires CMC Medical Devices to Make Global Compliance Quick and Easy5.11.2025 13:00:00 CET | Press release
Expands Registrar Corp’s reach to support over 75% of the global medical device market. Registrar Corp, a global leader in regulatory compliance and technology solutions and a Paine Schwartz Partners portfolio company, today announced the acquisition of CMC Medical Devices (CMC), a Spain-based provider of medical device regulatory, clinical, and compliance consulting services. The combination of Registrar Corp’s global network and CMC’s clinical and technical expertise creates a unified partner to help medical device and in vitro diagnostic (IVD) manufacturers bring products to market faster and with greater confidence. “We’re proud to welcome CMC Medical Devices to the Registrar Corp family,” said Raj Shah, CEO of Registrar Corp. “Together, we offer medical device manufacturers a single partner to navigate complex regulations and access the U.S., EU, and other key global markets—so they can focus on innovation rather than compliance.” “Joining Registrar Corp enables us to deliver even
Cybersecurity Leader Armis Closes $435 Million Round at $6.1 Billion Valuation5.11.2025 13:00:00 CET | Press release
In a pre-IPO round led by Growth Equity at Goldman Sachs Alternatives and with significant participation from CapitalG, Armis accelerates on the path to $1 billion in ARR and a public offering Armis, the cyber exposure management and security company, today announced a pre-IPO funding round of $435 million, bringing the company’s valuation to $6.1 billion. The round was led by Growth Equity at Goldman Sachs Alternatives with major participation from CapitalG, and was joined by new investor Evolution Equity Partners, alongside several existing investors. The investment round comes amid continued growth, with the company recently surpassing $300 million in Annual Recurring Revenue (ARR), growing over 50%. Armis has worked with over 40% of the Fortune 100, including 7 of the Fortune 10, and helps protect leading organizations around the globe, including manufacturers, airlines, financial services firms, healthcare institutions, and state and federal agencies. Yevgeny Dibrov, CEO and Co-Fo
Macrobond Selected by T. Rowe Price to Support Evolving Research and Investment Workflows5.11.2025 13:00:00 CET | Press release
Macrobond, the global platform for macroeconomic and financial data, has been selected by T. Rowe Price to support the continued evolution of its cross-asset research and systematic strategy workflows. As financial institutions look to strengthen data-driven decision-making, the need for scalable technology and integrated platforms has never been more critical. T. Rowe Price’s decision to implement Macrobond reflects a broader commitment to enhancing research workflows with modern, flexible solutions built for the pace and complexity of today’s investment landscape. Meeting the Demands of a Dynamic Environment The ability to integrate complex data sets, streamline analysis, and support automation were key factors in the selection process. Macrobond’s API and flexible data infrastructure provided a strong foundation for collaboration. “T. Rowe Price is continually investing in technology to improve the efficiency and quality of our research processes,” said Tae Kim, Head of Fixed Income
Compass Pathways to Participate in Stifel 2025 Healthcare Conference5.11.2025 12:30:00 CET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in the Stifel 2025 Healthcare Conference in New York, NY at 10:40 am ET on Tuesday, November 11, 2025. A live audio webcast of these events will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. We are motivated by the need to find better ways to help and empower people with serious mental health conditions who are not helped by existing treatments. We are pioneering a new paradigm for treating mental health conditions focused on rapid and durable responses through the development of our investigational COMP36
Watchmaker Genomics Launches TAPS+, Expanding Multimodal Capabilities in Oncology Ahead of AMP 20255.11.2025 12:00:00 CET | Press release
- TAPS+ enables simultaneous detection of methylation and genetic variants, unlocking new insights for precision oncology and translational research. - Preserves DNA integrity in challenging clinically relevant samples, including FFPE tissue and circulating tumor DNA (ctDNA). - Platform-agnostic chemistry enables seamless integration across sequencing systems. Watchmaker Genomics today announced the launch of TAPS+, a next-generation technology that unites genetic and epigenetic readouts from the same DNA molecule. By capturing multiple biological dimensions in a single assay, TAPS+ delivers a richer, more comprehensive view of tumor biology, with the power to advance applications in translational oncology, early cancer detection, therapy response monitoring, fragmentomics, and minimal residual disease assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251105264633/en/ Watchmaker Genomics launches TAPS+, a next-gener
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom